Zenpep and Colestipol: Primary Indications
Zenpep (pancrelipase) is used for exocrine pancreatic insufficiency, while colestipol is used for lowering LDL cholesterol in primary hyperlipidemia. These are two completely different medications for distinct conditions.
Zenpep (Pancrelipase)
Zenpep is FDA-approved specifically for the treatment of exocrine pancreatic insufficiency (EPI) in adult and pediatric patients 1. This condition occurs when the pancreas cannot produce adequate digestive enzymes.
Primary Conditions Requiring Zenpep:
- Cystic fibrosis - the most common indication, where pancreatic enzyme deficiency leads to malabsorption 1
- Chronic pancreatitis - progressive pancreatic damage reduces enzyme production 2, 3
- Pancreatectomy - surgical removal of pancreatic tissue 4
Clinical Benefits:
Zenpep contains lipase, protease, and amylase enzymes that:
- Reverse steatorrhea (fatty stools)
- Prevent weight loss and improve nutritional status
- Improve coefficient of fat absorption (CFA) by 24-36% compared to placebo 3, 5
- Reduce gastrointestinal symptoms including abdominal pain, diarrhea, and stool frequency 6, 5
The medication is delivered as enteric-coated pellets that release enzymes at approximately pH 5 in the duodenum 1.
Colestipol
Colestipol is FDA-approved as an adjunct to diet for lowering LDL cholesterol in patients with primary hyperlipidemia 7.
Mechanism and Use:
Colestipol is a bile acid sequestrant (BAS) that:
- Binds bile acids in the intestine, preventing their reabsorption
- Forces the liver to convert more cholesterol into bile acids
- Increases hepatic LDL receptors, clearing LDL from blood
- Reduces LDL-C by 16-27% depending on dose (5-15 g/day) 7
Clinical Context:
According to 2022 ACC guidelines, colestipol may be considered in patients with baseline LDL-C ≥190 mg/dL who achieve less than 50% LDL-C reduction on maximally tolerated statin plus ezetimibe therapy, with fasting triglycerides ≤300 mg/dL 7, 8. This represents third-line therapy after statins and ezetimibe.
Important Limitations:
- No cardiovascular outcomes data exist for colestipol (unlike cholestyramine, which showed 19% reduction in CHD death/MI in the LRC-CPPT trial) 7
- Common side effects include constipation, dyspepsia, and nausea 7
- Significant drug-drug interactions require other medications be taken 4 hours before colestipol 7
- May worsen hypertriglyceridemia 7
Common Pitfall:
Do not confuse bile acid sequestrants used for cholesterol lowering with their occasional off-label use for hepatic pruritus 9. For cholesterol management, colestipol is now relegated to a limited role given the availability of more effective therapies (PCSK9 inhibitors, bempedoic acid) with better tolerability profiles.